muramylnac-ala-isogln-lys-tripeptide has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deodhar, S; Gautam, S | 1 |
| Braun, DG; Brownbill, AF; Dukor, P; Schumann, G | 1 |
2 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Experimental Neoplasms
| Article | Year |
|---|---|
Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; C-Reactive Protein; Complement System Proteins; Cytotoxicity, Immunologic; Drug Carriers; G(M1) Ganglioside; Glycosphingolipids; Immune Sera; Immunoglobulins; Isoantibodies; Liposomes; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neutralization Tests | 1989 |
Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Administration, Intranasal; Animals; Cells, Cultured; Female; Immunity, Cellular; Immunotherapy; Leukocytes; Lung; Macrophages; Mice; Neoplasms, Experimental; Neutrophils; Phosphatidylethanolamines; Rats; Time Factors | 1985 |